Compare Immunovant Inc. Common Stock (IMVT) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Newmont Corporation — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B), while Newmont Corporation trades at $117.94 (market cap $121.75B). The key difference: Newmont Corporation is far larger — about 19.5× Immunovant Inc. Common Stock's market cap, and Newmont Corporation pays a 0.9% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Newmont Corporation for 58 Days on average.
| IMVT | NEM | |
|---|---|---|
Market Cap | $6.25B | $121.75B |
Volume | 1,755,411 | 5,421,125 |
Sector | Health | Basic Materials |
52-Week High | $44.96 | $135.14 |
52-Week Low | $17.03 | $78.63 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $5.35B | $118.34B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Newmont (NEM) trades at $113.54, down 2.45% on the day, amid a bearish technical signal but strong fundamental performance. The company reported record free cash flow of $5.3 billion in H1 2026 and has beaten earnings estimates for three consecutive quarters. Revenue grew to $22.67 billion in 2025 with a net income margin of 33.36%, while analyst consensus remains strongly bullish with a $136.83 price target.
The stock presents a compelling value opportunity with a P/E of 14.32 and robust profitability, though near-term technical weakness and gold price volatility pose risks. Upside potential is supported by operational improvements and shareholder returns, but investors must weigh macroeconomic factors affecting the gold sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
